Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) is now available.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has successfully completed the placement of 5,918,000 new H shares, raising approximately HK$1,943.0 million. The proceeds will primarily fund research and development, clinical trials, and product commercialization, enhancing the company’s market position and growth potential.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on research and development, clinical trials, and commercialization of biopharmaceutical products.
Average Trading Volume: 784,189
Technical Sentiment Signal: Buy
Current Market Cap: HK$79.41B
See more insights into 6990 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue